Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malign
A phase 1/2 trial of Acalabrutinib in mantle cell lymphoma, run by AstraZeneca, active and no longer recruiting.
Overview
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies is a phase 1/2 interventional study registered as NCT03932331 by AstraZeneca, with 105 participants enrolled, started 2020-04-29 and due to reach its primary completion in 2022-12-22. Interventions recorded: Acalabrutinib. Conditions listed: Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAn Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Shares Acalabrutinib, Mantle cell lymphoma, AstraZeneca.
- TrialA Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
Shares Acalabrutinib, Mantle cell lymphoma, AstraZeneca.
- TrialA Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
Shares Acalabrutinib, Mantle cell lymphoma, AstraZeneca.
- TrialA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Shares Acalabrutinib, Mantle cell lymphoma, AstraZeneca.
- TrialACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Shares Acalabrutinib, AstraZeneca.
- TrialA Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Shares Acalabrutinib, AstraZeneca.
- TrialAn Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
Shares Acalabrutinib, AstraZeneca.
- TrialStudy of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Shares Acalabrutinib, AstraZeneca.